Quick Answer
Tango Therapeutics, Inc. reported Operating Income Loss of -$111.29 million for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +23.6% in Operating Income Loss from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$472.00 | Q3 2020: -$26.76 million | Q1 2021: -$12.08 million | Q2 2021: -$4.56 million | Q3 2021: -$19.57 million | Q1 2022: -$25.38 million | Q2 2022: -$25.20 million | Q3 2022: -$29.92 million | Q1 2023: -$30.29 million | Q2 2023: -$23.25 million | Q3 2023: -$25.63 million | Q1 2024: -$42.26 million | Q2 2024: -$29.55 million | Q3 2024: -$32.88 million | Q1 2025: -$42.53 million | Q2 2025: -$40.97 million | Q3 2025: $14.07 million.
- Over the full 6 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Operating Income Loss has declined by 113.2%.
- Historical annual values: Fiscal year 2025: -$111.29 million | Fiscal year 2024: -$145.60 million | Fiscal year 2023: -$114.17 million | Fiscal year 2022: -$111.07 million | Fiscal year 2021: -$58.19 million | Fiscal year 2020: -$52.20 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: